TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05802095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental Feeding Tube Device
Description: One end of the catheter is in such a way that milk comes into the bottle. The tip of the feeding catheter can be fixed to the mother's breast with a plaster so that it is in the baby's mouth. The tip of the catheter is placed inside the baby's mouth while the baby is sucking on its mother. While the mother is breastfeeding, milk is supplied to the baby from both the mother and the bottle. The baby will continue to suckle as he feels that plenty of milk is coming. To increase the flow of milk from the bottle, the mother hangs the bottle around her neck with the teat side down. The higher the bottle or milk container is held, the greater the flow of milk. It is an easy and safe method.
Study: NCT06452433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gumarontinib
Description: 300 mg , qd ,po, expect 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Description: According to the actual situation of patients. Take as recommended, expect 6 months.
Study: NCT05765929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Description: Patients will be treated with a walker-orthosis for 6 weeks. Weightbearing as tolerated
Study: NCT06536634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAES
Description: The experimental intervention consists of SAES with a glove or adhesive electrodes at 20Hz, 300µs, intensity between 2-10mA, during 30 minutes per day, 5x/week, for 5 weeks, combined with conventional occupation therapy. The subsequent therapy sessions will take place at home, with in-between telephone checks.

Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: Treatment as usual
Study: NCT04340700

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC or Placebo
Description: A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC or Placebo
Description: A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber. The first THC dose is 8 mg, followed by approximately three doses of 2 mg each. Placebo will also be administered through a Volcano Vaporizer via inhalation. The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
Study: NCT04742400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib 120mg
Description: 120 mg orally
Study: NCT05692752

Intervention type: OTHER
Intervention: No intervention
Description: Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Intervention type: OTHER
Intervention: No intervention
Description: Expression of miR-133a \&208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
Study: NCT05031871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection ；INS068 injection；SHR20004 injection
Description: HR17031 injection dose+INS068 injection dose+SHR20004 injection dose+(INS068+SHR20004) injection dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection ；INS068 injection；SHR20004 injection
Description: INS068 injection dose+(INS068+SHR20004)injection dose+ HR17031 injection dose +SHR20004 injection dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection ；INS068 injection；SHR20004 injection
Description: SHR20004 injection dose+ HR17031 injection dose +(INS 068+SHR20004) injection dose+ INS068 injection dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection ；INS068 injection；SHR20004 injection
Description: (INS 068+SHR20004) injection dose+ SHR20004 injection dose+ INS068 injection dose+ HR17031 injection dose
Study: NCT04968249

Intervention type: OTHER
Intervention: Observational
Description: Observational Cohort to understand risk factors for early COPD.
Study: NCT05543070

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Electron Beam/3D-CRT/IMRT/VMAT
Study: NCT05064865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried table grape powder
Description: Consumption of 46g/day freeze-dried table grape powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of the table grape powder
Description: Consumption of 46g/day placebo version of the freeze-dried table grape powder
Study: NCT06522516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based caregiving training
Description: This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based caregiving training
Description: This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family resilience intervention
Description: The intervention will be developed based on the Maccubbin Family Resilience Theory, and Delphi methods. The content will contain 8 topics and be incorporated into caregiving training manual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual service
Description: This means the usual service provided by the local community health center from nurses during bi-weekly home visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual service
Description: This means the usual service provided by the local community health center from nurses during bi-weekly home visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual service
Description: This means the usual service provided by the local community health center from nurses during bi-weekly home visit.
Study: NCT06311539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband Strengthening Exercise Program
Description: Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband Strengthening Exercise Program
Description: Resisted knee flexion in prone position and resisted knee extension in seated position (for dominant leg) and bilateral squats were practiced in 3 sets of 12 repetitions. Participants rested for 30 seconds between sets. The program, which lasted approximately 30 minutes in total, continued for a total of 6 weeks, the first 3 weeks with the red theraband and the last 3 weeks with the black theraband.~15 morning type participants will be included in the morning exercise program (08:00) and 15 morning type participants will be included in the evening exercise program (18:00).~15 evening type participants will be included in the morning exercise program (08:00) and 15 evening type participants will be included in the evening exercise program (18:00).
Study: NCT05469321

Intervention type: OTHER
Intervention: None, pure observationnal study
Description: None, pure observational study following the usual management of the patients
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm Ultrasound
Description: Ultrasound of the Diaphragm at the end of inspiration and expiration

Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm Ultrasound
Description: Ultrasound of the Diaphragm at the end of inspiration and expiration

Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm Ultrasound
Description: Ultrasound of the Diaphragm at the end of inspiration and expiration
Study: NCT03921164

Intervention type: PROCEDURE
Intervention: Trans-oesophageal Doppler
Description: As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta.
Study: NCT05719610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey Exercises for Balance Training
Description: Group of Exercises used to Increase balance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swiss Ball Exercises
Description: Swiss Ball Exercises
Study: NCT06129487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative pictorial warning labels for alcoholic beverages
Description: Pictorial warning labels consisting of text and narrative imagery (e.g., photos of cancer patients) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-narrative pictorial warning labels for alcoholic beverages
Description: Pictorial warning labels consisting of text and non-narrative imagery (e.g., images of diseased organs) conveying the risk of alcohol for oral cancer, esophageal cancer, and larynx cancer.
Study: NCT06276179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patient will receive a bolus dose of 0.15 mg/kg plus 20 ml bupivacaine 0.25% followed by an infusion 0.03 mg/kg/h oxycodone plus 0.1 mL/Kg/h bupivacaine 0.125%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patient will receive a bolus 20 ml bupivacaine 0.25% followed by an infusion 0.1 mL/Kg/h bupivacaine 0.125%.
Study: NCT05549128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: The red laser (DMC) will be applied with the aim of reducing the anxiety of children during the dental consultation. It will be continuously and directly with 60J of energy, wavelength of 660nm and 100mW/cm2 of power. The application will be located in the unilateral radial artery for 10 minutes. The laser will be transmitted through an appropriate bracelet where the laser tip fits perfectly. It is a painless, non-invasive method that does not cause any discomfort during application.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation sham
Description: The red laser (DMC) will be applied off. I
Study: NCT06370195

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive rehabilitation
Description: The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation
Description: The study lasted 10d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT05882981

Intervention type: OTHER
Intervention: Sit and reach test
Description: It will be used to measure the flexibility of the participants.

Intervention type: OTHER
Intervention: Sit and reach test
Description: It will be used to measure the flexibility of the participants.

Intervention type: OTHER
Intervention: Hand grip strength measurement
Description: Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.

Intervention type: OTHER
Intervention: Hand grip strength measurement
Description: Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.

Intervention type: OTHER
Intervention: Back-leg-chest muscle strength measurement
Description: An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: Diaphragm Ultrasound
Description: Ultrasound of the Diaphragm at the end of inspiration and expiration
Study: NCT05882981

Intervention type: OTHER
Intervention: Back-leg-chest muscle strength measurement
Description: An analog Back Leg-Chest dynamometer will be used to evaluate general muscle strength.

Intervention type: OTHER
Intervention: Functional performance
Description: Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).
Study: NCT05882981

Intervention type: OTHER
Intervention: Functional performance
Description: Single-leg and double-leg horizontal jump test will be used to evaluate lower extremity functional performance. The tests will be carried out according to the Eurofit test battery (Council of Europe, 1988).

Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity will be evaluated with six minute walk test according to the ATS criteria.

Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity will be evaluated with six minute walk test according to the ATS criteria.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of respiratory mouth pressure
Description: Inspiratory and expiratory Measurement of respiratory mouth pressure
Study: NCT03921164

Intervention type: PROCEDURE
Intervention: Trans-thoracic echocardiography
Description: Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
Study: NCT04819347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.
Study: NCT03921164

Intervention type: PROCEDURE
Intervention: Applanation tonometry
Description: Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature.
Study: NCT06168071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
Study: NCT05306080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (IL-18BP)
Description: Tadekinig alfa will be administered via subcutaneous injection. The site of subcutaneous injection should be rotated to avoid injection site reactions; e.g. the outside of the thighs, arms, and the various quadrants of the anterior abdominal wall.~* Injection #1/Day 1:~  o Loading dose of 4 mg/kg; Maximum dose of 350 mg.~* Repeat Injection(s): 2 mg/kg/injection; Maximum dose of 160 mg/injection. Missed doses will not be made up.~  * Injection #2/Day 3: Approximately 48 hours (+/- 5 hours) after receipt of the 1st injection.~ * Injection #3/Day 5: Approximately 48 hours (+/- 5 hours) after receipt of the 2nd injection.~ * Continued Dosing (Optional): Approximately q48-72 hours; If the subject is responsive to initial therapy, but has ongoing symptoms of CRS/CRHLS.
Study: NCT05270694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Health Intervention Package
Description: The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of respiratory mouth pressure
Description: Inspiratory and expiratory Measurement of respiratory mouth pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: SNIP
Description: Measurement of Sniff Nasal Inspiratory Pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: SNIP
Description: Measurement of Sniff Nasal Inspiratory Pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: SNIP
Description: Measurement of Sniff Nasal Inspiratory Pressure
Study: NCT06480500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride
Description: 55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-CBT (Internet-based Cognitive Behavioural Therapy)
Description: Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
Study: NCT05903001

Intervention type: DIAGNOSTIC_TEST
Intervention: SNIP
Description: Measurement of Sniff Nasal Inspiratory Pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walking distance
Description: The maximum walking distance achieved in 6 minutes

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walking distance
Description: The maximum walking distance achieved in 6 minutes